Yunkang Group Limited (HKSE: 2325.HK) Stock Competitors & Peer Comparison

Yunkang Group Limited (HKSE: 2325.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2325.HK stands at 348.3M. In comparison, 2359.HK has a market cap of 572.6B. Regarding current trading prices, 2325.HK is priced at HK$0.60 on the HKSE, while 2359.HK trades at HK$204.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2325.HK currently has a P/E ratio of -1.29, whereas 2359.HK's P/E ratio is 22.78. In terms of profitability, 2325.HK's ROE is +0.00%, compared to 2359.HK's ROE of +0.27%. Regarding short-term risk, 2325.HK is less volatile compared to 2359.HK. This indicates lower risk in terms of short-term price fluctuations for 2325.HK.Check 2359.HK's competition here

Yunkang Group Limited (HKSE: 2325.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2325.HK stands at 348.3M. In comparison, 2268.HK has a market cap of 88.4B. Regarding current trading prices, 2325.HK is priced at HK$0.60 on the HKSE, while 2268.HK trades at HK$80.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2325.HK currently has a P/E ratio of -1.29, whereas 2268.HK's P/E ratio is 54.83. In terms of profitability, 2325.HK's ROE is +0.00%, compared to 2268.HK's ROE of +0.16%. Regarding short-term risk, 2325.HK is less volatile compared to 2268.HK. This indicates lower risk in terms of short-term price fluctuations for 2325.HK.Check 2268.HK's competition here

Yunkang Group Limited (HKSE: 2325.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2325.HK stands at 348.3M. In comparison, 6127.HK has a market cap of 32.9B. Regarding current trading prices, 2325.HK is priced at HK$0.60 on the HKSE, while 6127.HK trades at HK$25.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2325.HK currently has a P/E ratio of -1.29, whereas 6127.HK's P/E ratio is 31.66. In terms of profitability, 2325.HK's ROE is +0.00%, compared to 6127.HK's ROE of +0.06%. Regarding short-term risk, 2325.HK is less volatile compared to 6127.HK. This indicates lower risk in terms of short-term price fluctuations for 2325.HK.Check 6127.HK's competition here

Yunkang Group Limited (HKSE: 2325.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2325.HK stands at 348.3M. In comparison, 9860.HK has a market cap of 2.7B. Regarding current trading prices, 2325.HK is priced at HK$0.60 on the HKSE, while 9860.HK trades at HK$3.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2325.HK currently has a P/E ratio of -1.29, whereas 9860.HK's P/E ratio is 84.42. In terms of profitability, 2325.HK's ROE is +0.00%, compared to 9860.HK's ROE of N/A. Regarding short-term risk, 2325.HK is less volatile compared to 9860.HK. This indicates lower risk in terms of short-term price fluctuations for 2325.HK.Check 9860.HK's competition here

Yunkang Group Limited (HKSE: 2325.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2325.HK stands at 348.3M. In comparison, 2251.HK has a market cap of 966.9M. Regarding current trading prices, 2325.HK is priced at HK$0.60 on the HKSE, while 2251.HK trades at HK$9.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2325.HK currently has a P/E ratio of -1.29, whereas 2251.HK's P/E ratio is -35.89. In terms of profitability, 2325.HK's ROE is +0.00%, compared to 2251.HK's ROE of -0.02%. Regarding short-term risk, 2325.HK is similarly volatile compared to 2251.HK. This indicates similar risk in terms of short-term price fluctuations for 2325.HK.Check 2251.HK's competition here

Yunkang Group Limited (HKSE: 2325.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2325.HK stands at 348.3M. In comparison, 9960.HK has a market cap of 950.6M. Regarding current trading prices, 2325.HK is priced at HK$0.60 on the HKSE, while 9960.HK trades at HK$0.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2325.HK currently has a P/E ratio of -1.29, whereas 9960.HK's P/E ratio is -13.98. In terms of profitability, 2325.HK's ROE is +0.00%, compared to 9960.HK's ROE of -0.02%. Regarding short-term risk, 2325.HK is less volatile compared to 9960.HK. This indicates lower risk in terms of short-term price fluctuations for 2325.HK.Check 9960.HK's competition here

Yunkang Group Limited (HKSE: 2325.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2325.HK stands at 348.3M. In comparison, 8037.HK has a market cap of 605M. Regarding current trading prices, 2325.HK is priced at HK$0.60 on the HKSE, while 8037.HK trades at HK$0.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2325.HK currently has a P/E ratio of -1.29, whereas 8037.HK's P/E ratio is -3.03. In terms of profitability, 2325.HK's ROE is +0.00%, compared to 8037.HK's ROE of -0.31%. Regarding short-term risk, 2325.HK is less volatile compared to 8037.HK. This indicates lower risk in terms of short-term price fluctuations for 2325.HK.Check 8037.HK's competition here

Yunkang Group Limited (HKSE: 2325.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2325.HK stands at 348.3M. In comparison, 8247.HK has a market cap of 205.7M. Regarding current trading prices, 2325.HK is priced at HK$0.60 on the HKSE, while 8247.HK trades at HK$3.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2325.HK currently has a P/E ratio of -1.29, whereas 8247.HK's P/E ratio is -7.80. In terms of profitability, 2325.HK's ROE is +0.00%, compared to 8247.HK's ROE of N/A. Regarding short-term risk, 2325.HK is less volatile compared to 8247.HK. This indicates lower risk in terms of short-term price fluctuations for 2325.HK.Check 8247.HK's competition here

Yunkang Group Limited (HKSE: 2325.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2325.HK stands at 348.3M. In comparison, 0928.HK has a market cap of 190.6M. Regarding current trading prices, 2325.HK is priced at HK$0.60 on the HKSE, while 0928.HK trades at HK$0.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2325.HK currently has a P/E ratio of -1.29, whereas 0928.HK's P/E ratio is 13.29. In terms of profitability, 2325.HK's ROE is +0.00%, compared to 0928.HK's ROE of +0.01%. Regarding short-term risk, 2325.HK is less volatile compared to 0928.HK. This indicates lower risk in terms of short-term price fluctuations for 2325.HK.Check 0928.HK's competition here